A once-yearly PrEP? Gilead's lenacapavir shows promise as company plots phase 3
After Gilead’s lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart—only once a year.
After Gilead’s lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart—only once a year.
